Key facts
- Company: Verismo Therapeutics (Philadelphia), a subsidiary of HLB Innovation
- Licensed technology: PACK-IT in vivo CAR T engineering platform
- Licensor: Stanford Medicine (laboratory of Crystal Mackall, MD)
- Mechanism: T cell-targeted lentiviral particles deliver CAR genes to T cells
- Intended use: Off-the-shelf, in vivo delivery of KIR-CAR T cell therapies
- Platform: Multi-chain KIR-CAR (KIR plus DAP12 split signaling, NK cell-derived)
- Clinical programs: SynKIR-110 (NCT05568680); SynKIR-310 (NCT06544265)
- Indications studied: Mesothelin-expressing solid tumors; relapsed/refractory B-NHL
- Stage: Both candidates in phase 1; PACK-IT application preclinical
- Deal terms: Not disclosed
“Today, KIR-CAR is advancing along the established CAR T pathway in two [p]hase 1 clinical trials, and adding the PACK-IT technology is intended to extend the platform into next-generation, off-the-shelf in vivo delivery,” said Bryan Kim, CEO and cofounder of Verismo Therapeutics, in a company press release.¹
What does the PACK-IT technology do?
The PACK-IT platform uses engineered T cell-targeted lentiviral particles to deliver CAR genes directly to T cells.¹ It can be deployed in vivo, to reprogram a patient's own T cells in the body, or ex vivo in an accelerated workflow.¹ Stanford described the particles as carrying modified envelope proteins with antibodies that bind T cell surface receptors and direct viral entry, delivering the CAR gene without the usual activation and expansion steps.²
In preclinical data presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, PACK-IT generated CAR T cells with greater potency than conventional lentivirus. It also enabled in vivo generation of CD19-directed CAR T cells that controlled leukemia in preclinical models.¹,³
Why pursue in vivo CAR T engineering?
Approved CAR-T therapies are made ex vivo, a personalized process in which each patient's cells are collected, engineered, expanded, and quality tested in a facility over several weeks before being returned to the patient.¹ Verismo said that process has enabled the current generation of approved therapies, but its complexity can limit patient access and raise cost.¹ The company intends to apply PACK-IT primarily in an off-the-shelf, in vivo configuration, compressing the multi-week workflow into a same-day in vivo step.¹
How does the KIR-CAR platform differ from conventional CAR T?
KIR-CAR uses a multi-chain, split-signaling architecture derived from natural killer cells.¹ It pairs a KIR with DAP12 to separate target binding from T cell activation, giving a paired immune-receptor activation that is independent of CD3 signaling and does not require co-stimulation.¹ Verismo said the design is intended to eliminate the constant background activation and early T cell exhaustion seen with conventional single-chain CAR-T therapy.¹
What is in the clinic now?
Two KIR-CAR candidates manufactured ex vivo are in phase 1 trials: SynKIR-110 (NCT05568680) in mesothelin-expressing ovarian cancer, cholangiocarcinoma, and mesothelioma, and SynKIR-310 (NCT06544265) in relapsed or refractory B-cell non-Hodgkin lymphoma.¹,⁴ According to Verismo, initial STAR-101 data for SynKIR-110 presented at AACR 2026 showed a positive safety profile with dose-dependent efficacy signals and no dose-limiting toxicities. Initial CELESTIAL-301 data for SynKIR-310 included a complete response in a patient with follicular lymphoma at the lowest dose level, sustained beyond 6 months.¹
What are the limitations?
The release does not disclose financial terms of the license, a development timeline, or which KIR-CAR constructs will be paired with PACK-IT. PACK-IT data are preclinical and were presented in a conference abstract rather than a peer-reviewed journal, and Stanford's technology listing describes the platform as preclinical with in vivo work in progress.² The clinical results described are early phase 1 findings in small numbers of patients, reported by the company and not yet peer reviewed. No in vivo KIR-CAR candidate has entered clinical testing.
References
- Verismo Therapeutics. Verismo Therapeutics licenses in vivo CAR T engineering technology to extend its novel multi-chain KIR-CAR platform. Press release. Published November 18, 2026. Accessed November 18, 2026. https://prnmedia.prnewswire.com/news-releases/verismo-therapeutics-licenses-in-vivo-car-t-engineering-technology-to-extend-its-novel-multi-chain-kir-car-platform-302943157.html
- Stanford University. Rapid, programmable CAR-T cell engineering platform using antigen-targeted lentiviral particles. Docket S25-016. Accessed November 18, 2026. https://techfinder.stanford.edu/technology/rapid-programmable-car-t-cell-engineering-platform-using-antigen-targeted-lentiviral
- Burdsall KA, Xu P, Castro-Martinez D, et al. Abstract LB091: T cell targeted lentiviral gene delivery using the PACK-IT platform generates CAR-T cells with superior potency compared to conventional lentivirus and enables in vivo generation of CD19-CAR T cells capable of controlling leukemia in preclinical models. Cancer Res. 2025;85(8_Suppl_2):LB091. doi:10.1158/1538-7445.AM2025-LB091
- SynKIR-110 for mesothelin expressing ovarian cancer, cholangiocarcinoma or mesothelioma. ClinicalTrials.gov; NCT05568680. Updated June 24, 2026. Accessed November 18, 2026. https://clinicaltrials.gov/study/NCT05568680